Generic Name and Formulations:
Azelastine HCl 137mcg/spray; aqueous nasal spray; contains benzalkonium chloride.
Indications for ASTELIN:
Seasonal allergic rhinitis. Vasomotor rhinitis.
2 sprays in each nostril twice daily.
Seasonal allergic rhinitis: <5yrs: not established; 5–11yrs: 1 spray in each nostril twice daily. Vasomotor rhinitis: not established.
Avoid eyes. Pregnancy. Nursing mothers: monitor infants.
Potentiates CNS depression with alcohol, other CNS depressants. Caution with other antihistamines.
Bitter taste, headache, somnolence, dysesthesia, nasal burning, pharyngitis, dry mouth, paroxysmal sneezing, nausea, rhinitis, fatigue, dizziness, epistaxis, weight increase, myalgia. Children: also conjunctivitis, cough, asthma.
Ready-Spray—30mL (200 sprays)
Endocrinology Advisor Articles
- Long-Term Efficacy and Safety of Dapagliflozin for Type 1 Diabetes
- Measuring Time in Range During CGM May Be Useful Outcome Metric for Clinical Trials
- HbA1c Variability in General Population Increases Risk for Cardiovascular Events, All-Cause Mortality
- Safety and Effectiveness of the Most Common Bariatric Procedures Examined
- AHA, ADA Announce Joint Education Initiative to Reduce CVD Deaths in T2D
- High Circulating Prolactin Concentrations May Lower Risk for Type 2 Diabetes
- Online Tool Helps Patients With Advance Care Planning
- Dapagliflozin Lowers Heart Failure Hospitalization Rates in High-Risk Patients With Diabetes
- Direct-Acting Antiviral Therapy Reduced Risk for Incident T2D in Patients With Hepatitis C Infection
- Technological Breakthroughs in Medicine Move Physician-Patient Interactions From The Computer Screen Back to the Exam Room